This statement relates to the common stock, $.001 par value (the "Common Stock") of PhaseBio Pharmaceuticals, Inc. (the "Issuer") having its principal executive office at 1 Great Valley Parkway, Suite 30, Malvern, Pennsylvania 19355.
This statement is being filed by:
(a) New Enterprise Associates 13, L.P. ("NEA 13"); NEA Partners 13, L.P. ("NEA Partners 13"), which is the sole general partner of NEA 13; and NEA 13 GP, LTD ("NEA 13 LTD" and, together with NEA Partners 13, the "Control Entities"), which is the sole general partner of NEA Partners 13; and
(b) Peter J. Barris ("Barris"), Forest Baskett ("Baskett"), Patrick J. Kerins ("Kerins"), David M. Mott ("Mott"), Scott D. Sandell ("Sandell"), and Ravi Viswanathan ("Viswanathan") (together, the "Directors"). The Directors are the directors of NEA 13 LTD.
The persons named in this Item 2 are referred to individually herein as a "Reporting Person" and collectively as the "Reporting Persons."
The address of the principal business office of NEA 13 and each Control Entity is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of each of Barris, Kerins and Mott is New Enterprise Associates, 5425 Wisconsin Avenue, Suite 800, Chevy Chase, MD 20815. The address of the principal business office of Baskett, Sandell, and Viswanathan is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, California 94025.
The principal business of NEA 13 is to invest in and assist growth-oriented businesses located principally in the United States. The principal business of NEA Partners 13 is to act as the sole general partner of NEA 13. The principal business of NEA 13 LTD is to act as the sole general partner of NEA Partners 13. The principal business of each of the Directors is to manage the Control Entities, NEA 13 and a number of affiliated partnerships with similar businesses.
During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
NEA 13 and NEA Partners 13 are exempted limited partnerships organized under the laws of the Cayman Islands. NEA 13 LTD is an exempted company organized under the laws of the Cayman Islands. Each of the Directors is a United States citizen.
On October 17, 2018, the Registration Statement on Form S-1 filed with the Securities and Exchange Commission (the "SEC") by the Issuer (File No. 333-227474) in connection with its initial public offering of 9,200,000 shares of Common Stock (the "IPO") was declared effective. The closing of the IPO took place on October 22, 2018 (the "Closing"), and at such closing NEA 13 purchased an aggregate of 1,800,000 shares of Common Stock at the IPO price of $5.00 per share. In addition, prior to the IPO, NEA 13 purchased from the Issuer in a series of private transactions (i) 3,231,774 shares of Series B Redeemable Preferred Stock ("Series B Stock"), (ii) 260,865 shares of Series C-1 Redeemable Preferred Stock ("Series C-1 Stock"), (iii) 1,124,301 shares of Series D Redeemable Preferred Stock ("Series D Stock"), (iv) warrants to purchase 49,030 shares of Series B Redeemable Preferred Stock ("Series B Warrants"), and (v) warrants to purchase 181,190 shares of Series C-1 Redeemable Preferred Stock ("Series C-1 Warrants") for an aggregate purchase price of $43,059,465.71. Immediately prior to the closing of the IPO, these shares of Series B Stock, Series C-1 Stock and Series D Stock automatically converted to 4,616,940 shares of Common Stock. In addition, Series B Warrants and Series C-1 Warrants were net exercised and converted to 224,694 shares of Common Stock. NEA 13 now holds a total of 6,641,634 shares of the Issuer's Common Stock (the "NEA 13 Shares").
The working capital of NEA 13 was the source of the funds for the purchase of the NEA 13 Shares. No part of the purchase price of the NEA 13 Shares was represented by funds or other consideration borrowed or otherwise obtained for the purpose of acquiring, holding, trading or voting the NEA 13 Shares.